Here, we demonstrated that miR-34a through targeting amphiregulin, a ligand of EGFR, was a distinct signaling pathway in inhibition of HNSCC metastasis, which might be a potential therapeutic target of HNSCC. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.